<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The liver plays an essential role in maintaining <z:chebi fb="105" ids="17234">glucose</z:chebi> homeostasis, which includes insulin-mediated processes such as hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> output (HGO) and uptake, as well as in clearance of insulin itself </plain></SENT>
<SENT sid="1" pm="."><plain>In type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> [itself a potent inhibitor of hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> output (HGO)], alongside <z:e sem="disease" ids="C0020459" disease_type="Disease or Syndrome" abbrv="">hyperinsulinaemia</z:e>, indicates the presence of hepatic <z:hpo ids='HP_0008189'>insulin insensitivity</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Increased HGO is central to the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and highlights the need to target hepatic <z:hpo ids='HP_0008189'>insulin insensitivity</z:hpo> as a central component of <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering therapy </plain></SENT>
<SENT sid="3" pm="."><plain>The mechanisms underlying the development of hepatic <z:hpo ids='HP_0008189'>insulin insensitivity</z:hpo> are not well understood, but may be influenced by factors such as fatty acid oversupply and altered adipocytokine release from dysfunctional adipose tissue and increased liver fat content </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, although the impact of <z:hpo ids='HP_0008189'>insulin insensitivity</z:hpo> as a marker of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> is well known, the specific role of hepatic <z:hpo ids='HP_0008189'>insulin insensitivity</z:hpo> is less clear </plain></SENT>
<SENT sid="5" pm="."><plain>The pharmacological tools available to improve insulin sensitivity include the <z:chebi fb="0" ids="3095">biguanides</z:chebi> (<z:chebi fb="0" ids="6801">metformin</z:chebi>) and <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> (<z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>) </plain></SENT>
<SENT sid="6" pm="."><plain>Data from a number of sources indicate that <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi>, in particular, can improve multiple aspects of hepatic dysfunction, including reducing HGO, <z:hpo ids='HP_0008189'>insulin insensitivity</z:hpo> and liver fat content, as well as improving other markers of liver function and the levels of mediators with potential involvement in hepatic function, including fatty acids and adipocytokines </plain></SENT>
<SENT sid="7" pm="."><plain>The current review addresses this topic from the perspective of the role of the liver in maintaining <z:chebi fb="105" ids="17234">glucose</z:chebi> homeostasis, its key involvement in the pathogenesis of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and the tools currently available to reduce hepatic <z:hpo ids='HP_0008189'>insulin insensitivity</z:hpo> </plain></SENT>
</text></document>